Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma.
Cartier
A
A
Department of Chest Medicine, Hôpital du Sacré-Coeur, Montreal, Quebec, Canada.
Ghezzo
H
H
L'Archevêque
J
J
Trudeau
C
C
Malo
J L
JL
D000280:Administration, Inhalation; D000328:Adult; D000388:Air; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D016084:Bronchoconstriction / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003080:Cold Temperature / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D000068299:Salmeterol Xinafoate; D013997:Time Factors
D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol